HC Wainwright Reaffirms Buy Rating for Aptose Biosciences (NASDAQ:APTO)

HC Wainwright restated their buy rating on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report sent to investors on Friday,Benzinga reports. The firm currently has a $2.00 price target on the biotechnology company’s stock.

Separately, StockNews.com initiated coverage on Aptose Biosciences in a research note on Wednesday, January 8th. They issued a “hold” rating for the company.

Aptose Biosciences Stock Performance

NASDAQ APTO opened at $0.22 on Friday. The stock has a market cap of $13.24 million, a P/E ratio of -0.07 and a beta of 0.87. Aptose Biosciences has a fifty-two week low of $0.13 and a fifty-two week high of $2.48. The stock has a 50 day simple moving average of $0.25 and a two-hundred day simple moving average of $0.40.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC acquired a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences at the end of the most recent quarter. Hedge funds and other institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.